SCHEDULE 13G: Venrock Entities Disclose 8.2% Beneficial Ownership in CytomX Therapeutics

A group of Venrock-affiliated entities and individuals have filed a Schedule 13G, reporting a collective beneficial ownership of 8.2% of CytomX Therapeutics, Inc.'s common stock.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 12,992,500 shares of common stock of CytomX Therapeutics, Inc.
• This ownership represents 8.2% of CytomX Therapeutics, Inc.'s outstanding common stock.
• The percentage is based on 157,544,369 shares of common stock outstanding as of May 13, 2025, as disclosed in CytomX Therapeutics' prospectus supplement dated May 12, 2025.
• The shares are held across three entities: VHCP III (2,686,849 shares), VHCP Co-Investment III (268,945 shares), and VHCP EG (10,036,706 shares).
• The Reporting Persons share both voting and dispositive power over all 12,992,500 beneficially owned shares.
• The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. The presence of a significant institutional investor like Venrock could be viewed positively by the market.

Positives

• The disclosure of a significant institutional ownership stake by Venrock, a reputable healthcare capital firm, may signal confidence in CytomX Therapeutics' long-term prospects.

Negatives

• NA

Risks

• The document itself does not detail specific risks related to CytomX Therapeutics' operations or financial performance. It is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding CytomX Therapeutics' future performance or strategic outlook.

Industry Context

CytomX Therapeutics, Inc. operates in the biotechnology and pharmaceutical sector, focusing on developing novel cancer therapies. The filing indicates a significant investment by Venrock, a venture capital firm with a strong focus on healthcare and life sciences, which is consistent with investment trends in the biotech industry where specialized funds take substantial stakes in promising companies.

Related Party Transactions

• The filing details a group of related entities (Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC) and individuals (Nimish Shah, Bong Koh) acting as a group for the purpose of beneficial ownership reporting. This is a disclosure of their collective holdings, not a transaction by the issuer with a related party.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Venrock may influence investor perception and potentially the stock price, signaling institutional confidence or interest in CytomX Therapeutics.
• Management: Awareness of a large, coordinated ownership group may influence strategic decisions or engagement with the investor base.

Key Dates

Keywords

CytomX Therapeutics, Venrock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Healthcare Capital, Biotechnology, SEC Filing